KRAS and neoplasm: The anti-tumor trend of the PERK inhibitor in WT KRAS tumor cells with low ISR may be explained by the implication of PERK in p-eIF2 independent pathways like the stimulation of the nuclear factor erythroid 2-related factor 2 (NRF2)-HIF pathway in pancreatic and lung cancers54.